Patents by Inventor Tony Tianyi Wang

Tony Tianyi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting viral infection
    Patent number: 11427595
    Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 30, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, SRI INTERNATIONAL
    Inventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
  • COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION
    Publication number: 20200123170
    Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.
    Type: Application
    Filed: October 22, 2019
    Publication date: April 23, 2020
    Applicants: Trustees of Boston University, SRI International
    Inventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
  • Apolipoprotein E polypeptides and their use
    Patent number: 10125184
    Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 13, 2018
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF SOUTH CAROLINA
    Inventors: Tony Tianyi Wang, Shufeng Liu, Fan Daping
  • Aglaroxin C and derivatives as HCV entry inhibitors
    Patent number: 10085988
    Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 2, 2018
    Assignees: SRI International, Trustees of Boston University
    Inventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.